Skip to main content
Premium Trial:

Request an Annual Quote

FDA OKs Cequent IND for Oral RNAi Drug

Premium

Cequent Pharmaceuticals announced this week that its new drug application for an oral RNAi-based treatment for advanced familial adenomatous polyposis has been approved by the US Food and Drug Administration.

FAP is an inherited, colorectal cancer syndrome characterized by the growth of colorectal polyps. Though the polyps are initially benign, they become malignant in nearly all cases in the absence of colectomy, according to the company.

The drug, dubbed CEQ508, is designed to inhibit the oncogene beta-catenin, which is expected to prevent new polyp formation and possibly slow the progression to malignancy of existing ones.

The company said it is now working with the clinical center where a proposed phase I trial of the drug is to be run, the Fred Hutchinson Cancer Research Center in Seattle, to obtain the necessary institutional approvals. The study is slated to begin in early 2010.

Cequent first filed the IND in November (see RNAi News, 11/19/2009).

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.